185 related articles for article (PubMed ID: 35963480)
1. Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].
Saberzadeh-Ardestani B; Foster NR; Lee HE; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2022 Nov; 33(11):1159-1167. PubMed ID: 35963480
[TBL] [Abstract][Full Text] [Related]
2. Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147) (Alliance).
Lee H; Sha D; Foster NR; Shi Q; Alberts SR; Smyrk TC; Sinicrope FA
Ann Oncol; 2020 Apr; 31(4):487-494. PubMed ID: 32165096
[TBL] [Abstract][Full Text] [Related]
3. Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials.
Sinicrope FA; Chakrabarti S; Laurent-Puig P; Huebner L; Smyrk TC; Tabernero J; Mini E; Goldberg RM; Zaanan A; Folprecht G; Van Laethem JL; Le Malicot K; Shi Q; Alberts SR; Taieb J
Eur J Cancer; 2021 Feb; 144():101-112. PubMed ID: 33341444
[TBL] [Abstract][Full Text] [Related]
4. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer.
Sinicrope FA; Shi Q; Smyrk TC; Goldberg RM; Cohen SJ; Gill S; Kahlenberg MS; Nair S; Shield AF; Jahagirdar BN; Jacobson SB; Foster NR; Pollak MN; Alberts SR
JNCI Cancer Spectr; 2021 Oct; 5(5):. PubMed ID: 34485815
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy in stage II and III colon cancer: the role of the "budding and TILs-(tumor-infiltrating lymphocytes) combination" as tumor-host antagonists.
Lang-Schwarz C; Melcher B; Dregelies T; Norouzzadeh Z; Rund-Küffner S; Lang-Schwarz K; Vieth M; Sterlacci W
Int J Colorectal Dis; 2021 Aug; 36(8):1765-1779. PubMed ID: 33745027
[TBL] [Abstract][Full Text] [Related]
6. Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status.
Taieb J; Kourie HR; Emile JF; Le Malicot K; Balogoun R; Tabernero J; Mini E; Folprecht G; Van Laethem JL; Mulot C; Bouché O; Aparicio T; Michel P; Thaler J; Bridgewater J; Van Cutsem E; Perkins G; Lepage C; Salazar R; Laurent-Puig P;
JAMA Oncol; 2018 Jul; 4(7):e173695. PubMed ID: 29167892
[TBL] [Abstract][Full Text] [Related]
7. Immunoscore Is Prognostic in Low-Risk and High-Risk Stage III Colon Carcinomas Treated With Adjuvant Infusional Fluorouracil, Leucovorin, and Oxaliplatin in a Phase III Trial.
Sinicrope FA; Shi Q; Catteau A; Poage GM; Zemla TJ; Mlecnik B; Benson AB; Gill S; Goldberg RM; Kahlenberg MS; Nair SG; Shields AF; Smyrk TC; Galon J; Alberts SR
JCO Precis Oncol; 2022 Aug; 6():e2200010. PubMed ID: 35952316
[TBL] [Abstract][Full Text] [Related]
8. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
9. SCOT: Tumor Sidedness and the Influence of Adjuvant Chemotherapy Duration on Disease Free Survival (DFS).
Saunders MP; Iype R; Kelly C; Crosby J; Kerr R; Harkin A; Allan K; McQueen J; Pearson SR; Cassidy J; Medley LC; Raouf S; Harrison M; Brewster A; Rees C; Ellis R; Thomas AL; Churn M; Iveson T; Maka N
Clin Colorectal Cancer; 2023 Jun; 22(2):231-237. PubMed ID: 36967267
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer.
Efil SC; Guner G; Guven DC; Celikten B; Celebiyev E; Taban H; Akyol A; Isik A; Kilickap S; Yalcin S; Dizdar O
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102171. PubMed ID: 37352926
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
Sinicrope FA; Mahoney MR; Yoon HH; Smyrk TC; Thibodeau SN; Goldberg RM; Nelson GD; Sargent DJ; Alberts SR;
Clin Cancer Res; 2015 Dec; 21(23):5294-304. PubMed ID: 26187617
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
13. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer.
Malakorn S; Ouchi A; Hu CY; Sandhu L; Dasari A; You YN; Kopetz ES; Ellis LM; Chang GJ
Clin Colorectal Cancer; 2021 Mar; 20(1):e53-e60. PubMed ID: 33004292
[TBL] [Abstract][Full Text] [Related]
14. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
[TBL] [Abstract][Full Text] [Related]
15. No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study.
Ascierto PA; Marincola FM; Fox BA; Galon J
Oncoimmunology; 2020 Oct; 9(1):1826132. PubMed ID: 33194317
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers.
Fujimoto Y; Watanabe T; Hida AI; Higuchi T; Miyagawa Y; Ozawa H; Bun A; Fukui R; Sata A; Imamura M; Hirota S; Miyoshi Y
Breast Cancer; 2019 Nov; 26(6):738-747. PubMed ID: 31098866
[TBL] [Abstract][Full Text] [Related]
17. Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer.
Sinicrope FA; Shi Q; Hermitte F; Zemla TJ; Mlecnik B; Benson AB; Gill S; Goldberg RM; Kahlenberg MS; Nair SG; Shields AF; Smyrk TC; Galon J; Alberts SR
JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa023. PubMed ID: 32455336
[TBL] [Abstract][Full Text] [Related]
18. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH; Tougeron D; Shi Q; Alberts SR; Mahoney MR; Nelson GD; Nair SG; Thibodeau SN; Goldberg RM; Sargent DJ; Sinicrope FA;
Clin Cancer Res; 2014 Jun; 20(11):3033-43. PubMed ID: 24687927
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy.
Morris M; Platell C; Iacopetta B
Clin Cancer Res; 2008 Mar; 14(5):1413-7. PubMed ID: 18316563
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
